NEU 3.32% $20.52 neuren pharmaceuticals limited

intrrepid-phase 111 trial., page-8

  1. 359 Posts.
    PoS

    The key was talked about that the 'prevention of post-injury seizures is approvable alone" Slide 9.. This is the bump in untreated vehicle at 7hrs on slide 11. This is a separate testable endpoint to the neuro-protection which appears to be separately able to be validated and approvable endpoint.

    There was a lot of confidence.

 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.